SecBot SecBot
SECBOTREPLAY Home › Report › IDYA

IDYA · IDEAYA Biosciences reported Q2 2026 results with a net loss of $112.5M…

IDEAYA Biosciences, Inc. · 8-K filed Aug 4, 2026 at 06:01 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Aug 4, 2026 at 06:01 ET

IDEAYA Biosciences reported Q2 2026 results with a net loss of $112.5M ($-1.22/share), a wider loss than the prior quarter's $98.5M ($-1.11/share), driven by rising R&D spend ($108.7M vs $95.7M). The company highlighted ongoing NDA submission for darovasertib under RTOR, a new Roche collaboration for IDE892, and a strong cash position of ~$1.24B following a $323.4M June offering. The widening loss and lack of revenue growth (collaboration revenue of $8.9M is immaterial for a pre-commercial biotech) make this a neutral-to-slightly-bearish update, though the pipeline catalysts and cash runway into 2030 provide a floor.

  • Net loss of $112.5M for Q2 2026, compared to $98.5M in Q1 2026.
  • R&D expenses increased to $108.7M from $95.7M sequentially.
  • Cash, cash equivalents, and marketable securities of ~$1.24B as of June 30, 2026.
  • Completed a public offering in June 2026, raising ~$323.4M in net proceeds.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access